Neogen
Annual Report 2006

Plain-text annual report

Financial hiGhliGhtS Amounts in thousands, except per share Years Ended May 31, Operations: Total Revenues Food Safety Sales Animal Safety Sales Operating Income Net Income Basic Net Income Per Share Diluted Net Income Per Share 2006 2005 2004 2003 2002 $ 72,433 $ 62,756 $ 55,498 $ 47,685 $ 42,065 34,951 28,156 27,567 26,476 20,970 37,482 34,600 27,931 21,209 21,095 12,045 7,941 .96 .92 8,769 5,916 .73 .70 7,542 5,099 .64 .61 6,785 4,787 .63 .60 5,500 3,945 .53 .49 Average Diluted Shares Outstanding 8,644 8,492 8,377 7,985 7,972 total RevenueS (DollaRS in thouSanDS) net income (DollaRS in thouSanDS) total aSSetS (DollaRS in thouSanDS) In thousands May 31, Financial Strength: 2006 2005 2004 2003 2002 Cash and Marketable Securities $ 1,959 $ 1,972 $ 1,696 $ 8,897 $ 6,353 Working Capital Total Assets Long-Term Debt Stockholders’ Equity 26,252 22,644 20,619 22,208 19,651 88,290 63,884 59,975 48,036 40,270 9,955 - 3,900 - - 64,548 54,835 47,842 41,402 35,546 DeDicateD to FooD anD animal SaFety  a meSSaGe FRom the chaiRman The team just keeps winning! For the 13th consecutive year, I can report Neogen set a new record in both reve- nues and earnings. I couldn’t be prouder of this team of over 400 employees that continues to keep our long growth re- cord intact. JameS l. heRBeRt for Revenues our 2006 fiscal year were $72.4 million, a 15% increase. Net income for the year increased by 34% to $7.9 million as compared to $5.9 million a year ago. This translates to $0.92 per share for the 2006 year as compared with $0.70 per share last year. Not only has Neogen’s annual growth record been unusually strong, but the team record for quarterly per- formance is even more striking. Neogen now has over 53 consecutive profitable quarters from operations. We began building our quarterly revenue record 15 ½ years ago and now can claim 57 quarters of the last 62 to show “Being able to stand behind this record of results has undoubtedly enabled us to... provide an exceptional investment opportunity for our shareholders.” revenue increases on a year over year comparison. Being able to stand behind this record of results has undoubtedly enabled us to earn customer confi- dence, hire outstanding employees, receive great coop- eration in the communities in which we operate, and provide an exceptional investment opportunity for our shareholders. Balance Sheet StRonG Neogen generated approximately $12.3 million in cash from operations during the year. That cash along with some bank borrowing allowed us to make two attractive acquisitions and expand our facilities and equipment requirements for profitable future growth. Though at year end our balance sheet shows $10 mil- lion in bank borrowing, that full amount was retired as a result of the successful completion of a 650,000 share stock offering the beginning of June. This leaves the company debt free, significant cash generation, and an unused bank line of credit of $17.5 million. Neogen also continued its solid growth in shareholder value as shareholder equity increased by 18%—the 13th consec- utive year of equity increase. Both DiviSionS SoliD Neogen manages its business as two divisions – Food Safety and Animal Safety. Both generated strong results for the past year. total RevenueS (DollaRS in thouSanDS) Our Animal Safety Division had the highest reve- nues for the year at approximately $37.5 million. These revenues were 8% higher than a year ago, and all of those results came from organic growth. Vaccine prod- uct sales showed an increase of 11% for FY ’06 follow- ing a 15% increase we experienced in FY ’05. The re- sults from our vet- erinary instrument group also showed good year to year comparisons with revenues up 15% for FY ’06 follow- ing a 33% increase in FY ’05. This has allowed Neogen to be an even greater factor in serving the nation’s farm- ers and ranchers as they improve food safety back in- side the farm gate. The greatest increase in revenue growth came from our Food Safety Division with revenues ap- proaching $35 million—up 24% compared to last year. After struggling a bit in FY ’05 with only a 2% increase in revenue, this group turned in good results on or- ganic growth, and the beginning of some exciting new growth opportunities. Sales of diagnostic products for the detection of nat- ural toxins, drugs, and allergens led the way with sales up 51%. Dehydrated culture media operations were up 13% for FY ’06 even following the strong results for FY ’05. Sales of diagnostic tests for the detection of bacteria and general sanitation showed an increase compared to a decrease in the prior year. This turnaround is in line with the expected improved results we communicated to shareholders last year. inteRnational GRowth continueS Studies indicate that as much as 66% of Neogen’s potential revenue lies outside the U.S. This has dictated the company should continue to look for international marketing opportunities. In FY ’06, international sales accounted for 29% of total revenue. These results follow the established trend from 27% last year and 25% the preceding year.  neoGen coRPoRation Over the past two years, Neogen has expanded its Neogen Europe Ltd. operations in Scotland as the center of distribution and focal point of our business development in the EU countries. Revenues from our European operations increased 14% this year. conSoliDation exPanDS eFFiciency Productivity improvements as well as better utili- zation of our facilities drove operating income to over $12 million for the year – a 37% improvement as com- pared to last year. A part of this came through an in- crease in gross margins to 51.1% this year as compared to 48.8% last year. Investments in ’06 in both equipment and additional facilities should allow us to continue these improvements going forward. StRateGic acquiSitionS comPleteD During the year, we made some strategic acquisi- tions that will be important to the company’s future growth. At the end of December, we completed the ac- quisition of the dairy antibiotic test kit business from Belgium based UCB and announced our intention to re- locate that manufacturing facility from Barcelona, Spain to Lansing. I’m pleased that in June we had successfully relocated that entire business and were producing prod- uct for our worldwide customer base without interrup- tion of supply to our customers. It is estimated that the worldwide market for testing of antibiotic residues in milk approaches $60 million. For the last full year of operation prior to our acquisition, revenues were approximately $8.5 million. We believe there is good worldwide growth opportunity for dairy diagnostic tests. We are currently seeking FDA approval for the diagnostic tests that would open the sizeable U.S. market opportunity. In StockholDeRS’ equity (DollaRS in thouSanDS) late February, Neogen acquired Centrus International from Eastman Chemical. Again, we ac- quired an important product for the testing of general microbial contamination where we had not enjoyed any unique product advantages earlier. Significant por- tions of this busi- ness will also be moved to Lansing where the com- pany has an out- standing group of microbiologists in R&D and technical services. Though Centrus had rev- enues of less than $3 million during its last year un- der Eastman ownership, we believe Neogen has good growth opportunities with this product also. During the year, Neogen also acquired a 55,000 square foot building near its Lansing campus. Remodeling has now begun on this facility that will al- low for some important increase in staffing in our R&D activities, consolidation of vaccine production from Tampa, and provide space for future growth. oRGanizational chanGeS In May, we lost a member of the Board of Directors and a personal friend with the death of Ted Doan. Ted served as a member of the Board for almost 24 years and his encouragement was important. We appreciate the legacy Ted left us. In June, Jack Parnell stepped down as Chairman of Neogen’s Board where he has played an important role for the company since 2001, but will continue as a member of the Board. I was elected as Chairman of the Board and Chief Executive Officer, and Lon Bohannon was elected President and Chief Operating Officer. It was very appropriate at Neogen’s stage of growth that we adjust some areas of responsibility to get the right people in the right places to continue to drive our future growth. Lon’s knowledge of our busi- “Investments in ’06 in both equipment and additional facilities should allow us to continue these improvements going forward.” ness, impeccable business judgement, demonstrated leadership ability, and unquestionable personal and corporate ethics clearly makes him the right person to drive that growth. I have worked side-by-side with Lon for 21 years since he joined the company as Controller, moved to Chief Financial Officer, and then COO. I don’t intend to retire, but instead continue to work with Lon in strategic areas that are going to be important to our growth as we begin to focus on the $200 million rev- enue mark. The continued worldwide emphasis on food safety and animal safety will undoubtedly allow us to con- tinue to provide the results that our customers, share- holders, and employees rely upon. James L. Herbert Chairman & CEO DeDicateD to FooD anD animal SaFety  We Stand Behind Our Results People are drawn to Neogen in a variety of ways. Customers come seeking a solution for a food or animal safety concern. Investors come seeking a solid investment, and distributors come to align with a profitable business partner. Leaders in Neogen’s home communities come to build relationships for the mutual benefit of the company and communities. New employees come seeking challenging careers with a company that matches their limitless potential. No matter how they arrive at Neogen, they all are seeking one thing: a solid, stand-up company that stands behind its results. When a food producer uses a Neogen test to determine whether a product sample contains a dangerous contaminant before shipping the product to consumers, he wants to know that Neogen stands next to him throughout the testing process. When a horse care provider vaccinates a promising foal with Neogen’s vaccine, she wants to do so with a product from a company with a proven track record. When a private investor is evaluating the company for a possible purchase of Neogen stock, he wants to know the financial results he is analyzing are beyond reproach. From supplying products to be used to ensure safety from inside farm gates to dinner plates around the world, to achieving consistent growth in sales and profitability, to the way it conducts its everyday operations, Neogen produces results that it proudly stands behind.   neoGen coRPoRation neoGen coRPoRation  More than 15 years of excellent financial performance Increased positive notice in the investment community Products customers can trust Increasing product offerings through internal research and development Increasing product offerings through acquisition Adding jobs, and retaining key employees Improving Neogen home communities DeDicateD to FooD anD animal SaFety DeDicateD to FooD anD animal SaFety  5 We Stand Behind Our Results ReSult More than 15 years of excellent financial performance Neogen completed its 2006 fiscal year by extending its string of profitable quarters from operations to 53—more than 13 straight years of profitability. With its recently completed fourth quarter, the company also marked the 57th quarter of the past 62 that Neogen showed a revenue increase as compared to the same time period from the prior year. That excellent record of performance now covers more than 15 years. Neogen’s 15 years of nearly unblemished revenue growth is reflected in the company’s compound annual growth rate of almost 20% over that time span. ReSult Increased positive notice in the investment community With Neogen’s continuing record of exceptional financial performance has come increasing recognition in the financial press and among investors. Recent notice has included: • For the fourth time in six years, Neogen was named to Forbes Magazine’s list of the 200 Best Small Companies in America. The annual list is based on growth in sales, earnings, and return on equity for the past five years, and the latest 12 months. • Neogen’s 2006 fiscal year also saw the company being chosen by the Russell Investment Group to be included in its new Russell Microcap Index. • The NASDAQ National Market chose Neogen to be included in its new top tier of listed companies, the Global Select Market. “Neogen is an example of an industry leader that has achieved superior listing standards, which clearly defines the essence of the Global Select Market,” NASDAQ Vice President Bruce Aust said in announcing the new market tier. ReSult Products customers can trust Since Neogen first developed rapid test kits more than 20 years ago, millions of food and animal feed samples have been tested for a dangerous pathogen, naturally occurring toxin or food allergen using a Neogen product. In those 20 years, there has never been a single recall or illness that would indicate a test result was wrong. Not one. The wide and expanding use of Neogen’s line of veterinary products on animals ranging from beloved companion pets to valuable livestock and performance animals provides compelling evidence that these products are safe and effective. Neogen’s customers face serious consequences if their products are contaminated with any of a number of well-established or emerging threats, including dangerous bacteria, spoilage bacteria, natural toxins, veterinary drug residues in meat and milk, unlabeled food allergens, sanitation concerns, broken veterinary needles, rodent filth, or other contaminants. No other company offers the breadth of products, variety of formats, and packaging options to provide the efficient solutions that food and animal safety customers are seeking.  neoGen coRPoRation annual report 2006 ReSult Increasing product offerings through internal research and development Neogen maintains a strong commitment to innovation through its R&D activities, with expected annual R&D expenditures to be maintained at about 5-6% of total company revenues. Neogen has ongoing development projects for new or improved diagnostic tests for the food safety, pharmacologics, and animal safety markets, as well as engineering projects for new or improved veterinary instruments. Recent innovations developed through Neogen’s internal efforts include: • Neogen’s new AccuPoint® ALP (alkaline phosphatase) Test. AccuPoint ALP uses the same luminometer used by the company’s AccuPoint ATP sanitation monitoring system to test for ALP—an enzyme naturally present in milk from mammals. Because ALP is destroyed only under conditions more severe than is required to kill most pathogens, tests for the presence of ALP have long been used in the dairy industry to ensure the effectiveness of pasteurization processes. Neogen’s new ALP test forms a strong complement to the company’s new dairy antibiotic tests. • The company’s new Reveal® for Total Milk Allergen lateral flow test adds to Neogen’s line of tests in the easiest and quickest format available for food allergens. The company also recently added food allergen tests for soy flour and hazelnut, which further solidifies Neogen’s status as the unquestioned leader as supplier of the most comprehensive line of food allergen testing products to the food industry. • Neogen’s new ThyroKare™ thyroid hormone replacement therapy offers key advantages over similar existing products on the companion animal market. ThyroKare joins an expanding, and increasingly successful, line of quality companion animal products that also includes UriCon™ Tablets for the control urinary incontinence; RenaKare™, a potassium supplement; UriKare™, a urinary acidifier; PanaKare™ Plus for the treatment of exocrine pancreatic insufficiency; and ImmunoRegulin®, an immune stimulant used to treatment Staph. pyoderma in dogs. • Neogen’s new LESS (Listeria Enrichment Single Step) culture medium trims the incubation time needed to detect Listeria in environmental samples to 24 hours, from 48 hours or longer for most other test systems. The new single-step medium also eliminates the need for two separate enrichment media to detect the dangerous foodborne pathogen. • Neogen’s new forensic drug detection assay format makes the testing process even easier. Thus far, Neogen has enhanced 10 of its extensive line of approximately 80 forensic drug detection tests with the improved format, including tests for LSD, cocaine, PCP, opiates, barbiturates, THC, and amphetamines. This family of drug test kits is also used to detect drugs of abuse in eventing animals, and drugs of all types in food products. Four additional tests in the improved format are scheduled for release in the 2007 fiscal year. DeDicateD to FooD anD animal SaFety  We Stand Behind Our Results ReSult Increasing product offerings through acquisition • Neogen’s acquisition of Centrus International from Eastman Chemical provided Soleris™, a user-friendly, rapid optical testing system that accurately detects microbial contamination. Soleris provides the company a product line to effectively compete in the general microbial rapid test market. Unlike Neogen’s tests for dangerous pathogens such as E. coli O157:H7, Salmonella and Listeria, the focus of the Soleris system is bacteria associated with poor food quality and spoilage. Of the 36 market segments served by Neogen’s Food Safety Division, 29 have been identified as potential users of the Soleris system. The worldwide market for the general microbiology testing that Soleris targets is estimated to be approximately $200 million a year. With significant unused lines of credit and strong quarter-to-quarter cash generation, Neogen continues to have the capability to pursue synergistic acquisitions that provide access to new markets, and provide new product offerings for established markets. Recent Neogen acquisitions include: • Neogen’s acquisition of UCB’s dairy antibiotic testing business provided the company access to the worldwide market for antibiotic testing of milk, which has been estimated to exceed $60 million. A significant portion of that total market is in the United States, where virtually every load of raw milk delivered to dairy processing plants is tested for antibiotic residues. Neogen continues to anticipate a key U.S. FDA approval for the domestic use of its advanced BetaStar® dairy antibiotic testing product within its 2007 fiscal year. The dairy antibiotic testing kits represent a strong complementary fit with other testing products that Neogen offers the dairy industry. ReSult Adding jobs, and retaining key employees With news of corporate layoffs and job migration filling the business pages, job security remains a major employee concern. In these turbulent times, Neogen has succeeded in providing a more stable work environment for its increasing roster of employees. While other companies are cutting back, Neogen has judiciously added employees to meet the increased staffing demands that accompany substantial internal growth and acquired product lines. Most of Neogen’s key management staff have been with the company for at least 10 years, and many other key positions are filled with employees who have been with Neogen for at least 5 years. An employee stock purchase program that was initiated in 2002 has helped further instill a pride of ownership. Neogen believes employee-owners are more committed to achieving success, and better understand the importance of building and maintaining beneficial relationships with co-workers, investors, and customers.  neoGen coRPoRation annual report 2006 Before After Although groups come to Neogen for a number of reasons, they are all seeking one thing—results. Neogen is proud to stand behind the results it provides to investors, customers, employees, and communities. Neogen has enjoyed similar mutually beneficial relationships in Lexington, Ky., Randolph, Wisc., and Ayr, Scotland, as the company continues to help expand community employment and tax bases. In FY 2004, Neogen made the decision to stay and grow in Lexington when it purchased and moved into an 80,000 square foot facility. Also in FY 2004, the Scottish government worked with Neogen to assist the company with growing in Ayr, Scotland. Scotland’s assistance of Neogen Europe Ltd. has already paid off. Neogen Europe was recently awarded the Enterprising Scotland Award for International Business, Scotland’s top exporting business award. ReSult Improving Neogen home communities While Neogen strives to extend the reach of its products to improve food and animal safety throughout the world, the company also takes pride in improving the communities it calls home. The most visible results in improving Neogen’s home communities have taken place in Lansing, Mich., the company’s headquarters. Various city tax abatements over the company’s 24 years in Lansing have been repaid many times over as Neogen and city and state governments have continued to work together. Michigan Governor Jennifer Granholm said: “Michigan’s economy has long been a ‘one-legged stool’ because of an over-reliance on the automobile industry,” and “Companies such as Neogen can provide Michigan’s ‘second and third legs,’” at the October 2005 ribbon cutting of Neogen’s new 50,000 square foot manufacturing facility. The company created state-of-the-art dehydrated culture media and veterinary instrument production facilities, and numerous local jobs, from what had been a 95-year-old abandoned building near downtown Lansing. DeDicateD to FooD anD animal SaFety  manaGement’S DiScuSSion anD analySiS oF Financial conDition anD ReSultS oF oPeRationS The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen Corporation management does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results. Any statements contained herein that are not statements of historical fact may be deemed to be forward- looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In addition, any forward-looking statements represent management’s views only as of the day this Report on Form 10-K was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change. cRitical accountinG PolicieS anD eStimateS The discussion and analysis of the Company’s financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including those related to receivable allowances, inventories and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following critical accounting policies reflect management’s more significant judgments and estimates used in the preparation of the consolidated financial statements. Revenue Recognition Revenue from sales of products is recognized at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, which is generally at the time of shipment. Where right of return exists, allowances are made at the time of sale to reflect expected returns based on historical experience. Accounts Receivable Allowance Management attempts to minimize credit risk by reviewing customers’ credit histories before extending credit and by monitoring credit exposure on a regular basis. An allowance for possible losses on accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information, such as changes in overall changes in customer credit and general credit conditions. Actual collections can differ from historical experience, and if economic or business conditions deteriorate significantly, adjustments to these reserves could be required. Inventory A reserve for obsolescence is established based on an analysis of the inventory taking into account the current condition of the asset as well as other known facts and future plans. The amount of reserve required to record inventory at lower of cost or market may be adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations. Valuation of Intangible Assets and Goodwill Management assesses goodwill and other non-amortizable intangible assets for possible impairment on no less often than an annual basis. This test was performed in the fourth quarter of fiscal 2006 and it was determined that no impairment exists. There was also no impairment indicated for 2005 or 2004. In the event of changes in 0 neoGen coRPoRation manaGement’S DiScuSSion anD analySiS oF Financial conDition anD ReSultS oF oPeRationS circumstances that indicate the carrying value of these assets may not be recoverable, management will make an assessment at any time. Factors that could cause an impairment review to take place would include: • Significant under performance relative to expected historical or projected future operating results. • Significant changes in the use of acquired assets or strategy of the Company. • Significant negative industry or economic trends. When management determines that the carrying value of intangible assets may not be recoverable based on the existence of one or more of the above indicators of impairment, the carrying value of the reporting unit’s net assets is compared to the projected discounted cash flows of the reporting unit using a discount rate commensurate with the risk inherent in the Company’s current business model. If the carrying amounts of these assets are not recoverable based upon a discounted cash flow analysis, such assets are reduced by the estimated shortfall of fair value to recorded value. Changes to the discount rate or projected cash flows used in the analysis can have a significant impact on the results of the impairment test. ReSultS oF oPeRationS Executive Overview On an overall basis, the 2006 fiscal year had a 15% revenue increase in comparison with the fiscal year ended May 31, 2005, as a result of increases in each of the Company’s operating segments. A portion of the Food Safety segment’s revenue increases came from the Company’s December 2005 acquisition of the dairy antibiotic testing business of UCB and from the February 2006 acquisition of Centrus International Inc. Revenue from continuing product sales increased by 8%. This growth came as a result of the further implementation of the segment’s sales and marketing plans and continuing recognition of the ease of use and beneficial results from the Company’s products. Animal Safety sales grew 8% as the segment continues its aggressive approach to sales and marketing of its products. Gross margins increased by 2% to 51% for the year and net income was up 34% to $7,941,000. These increases resulted principally due to changes in product mix, acquisitions during the year, the effect of reorganizations during the past years and continued strong control of costs. Operating expenses declined in fiscal 2006 to 34% from 35% as the company continued its strong cost containment measures. Net income increased 34% to $7,941,000 in fiscal 2006 from $5,916,000 in 2005. RevenueS (dollars in thousands) Food Safety: Natural Toxins, Allergens & Drug Residues Bacterial & General Sanitation Dry Culture Media & Other Animal Safety: Life Sciences & Other Vaccine Rodenticides & Disinfectants Veterinary Instruments & Other Total Revenues Twelve Months Ended Increase Increase May 31, 2006 (Decrease) May 31, 2005 (Decrease) May 31, 2004 $ 16,633 10,115 8,203 $ 34,951 $ 4,553 2,837 10,651 19,441 $ 37,482 $ 72,433 51% 2% 13% 24% 5% 11% 7% 9% 8% 15% $ $ $ $ $ 10,982 9,943 7,231 28,156 4,331 2,564 9,941 17,764 34,600 62,756 5% (5%) 9% 2% 9% 15% 144% 1% 24% 13% $ $ $ $ $ 10,502 10,457 6,608 27,567 3,973 2,222 4,076 17,660 27,931 55,498 Within the Food Safety Segment, Natural Toxins and Allergens sales were up 51% in fiscal year 2006 in comparison with sales in 2005 and up 5% in fiscal year 2005 in comparison with 2004. A significant portion of the gain in FY 2006 resulted from the acquisition of the UCB dairy antibiotic testing business. Exclusive of the dairy antibiotic testing business, Natural Toxins and Allergens revenues increased by 18% in comparison with the 2005 fiscal year. Increases in diagnostic test kit sales to detect naturally occurring toxins such as aflatoxin continue to be realized due to superior technologies and marketing by the Company. Sales of food test kits to DeDicateD to FooD anD animal SaFety  manaGement’S DiScuSSion anD analySiS oF Financial conDition anD ReSultS oF oPeRationS detect the presence of harmful allergens continued to increase with the new labeling regulations in January 2006 and through the introduction of several new products during fiscal year 2006. The growth in this area is fueled by public and producer recognition of this food safety threat. Sales of Bacteria and General Sanitation products, including the sales of products contributed by the acquisition of Centrus International in February 2006, increased by 2% in fiscal year 2006 in comparison with fiscal 2005 but had declined by 5% from fiscal year 2004 to 2005. Sales of the AccuPoint ATP general sanitation test continued to gain momentum throughout fiscal year 2006 and 2005 following a move from an outside supplier of ATP product to a more user friendly and stable internally produced product with improved margins. Sales of diagnostic tests for the detection of bacteria have decreased marginally as a result of newer competition and some pricing erosion in the marketplace. Dry culture media and other sales increased by 13% in 2006 and by 9% in 2005 primarily as a result of increased market penetration both domestically and internationally. The Company’s focus on customer service and resolution of customer operating problems has resulted in acceleration in sales. Within the Animal Safety Segment, sales of life science and other products increased by 5% in fiscal year 2006 in comparison with 2005 and by 9% in 2005 in comparison with the 2004 fiscal year. Sales of forensic drug tests, TMB Substrates and diagnostic research kits each contributed to the sales growth as the Company continues to add business from the existing customer base as well as by adding new customers. Vaccine product sales increased by 11% in 2006 in comparison with 2005 and by 15% in fiscal 2005 in comparison with 2004, fueled by strong increases in sales in international markets, due in part to the new single dose product and equine practitioners who continue to purchase the immune stimulant vaccine for use against the deadly West Nile Virus in horses. Sales of Hacco rodenticides and Hess and Clark disinfectants continued to contribute to the 2006 sales increases and grew by 7% in 2006. Revenues from these products grew 144% in 2005 with a full year of sales, in comparison with a partial year in 2004 following the November 2003 acquisition. Rodenticide revenue increases in 2006 are also due to increased market penetration in OEM customers as well as from strong zinc phosphide sales in the Northwest due to vole outbreaks. Veterinary instruments and other sales increased in 2006 by 9% and increased by 1% in 2005. Fiscal year 2006 increases of 15% in Ideal Instrument veterinary products were offset by declines in revenues related to equine supplements, certain wound care and other products. In 2005 increases were driven by a 33% increase in sales of veterinary instruments including a 17% increase of sales of those products through retail chain distribution. Other 2005 growth contributors in this category include certain of the Company’s wound care products that nearly doubled in the 2005 year and the Company’s unique D3 detectable needle. coSt oF GooDS SolD (dollars in thousands) Costs of goods sold 2006 $ 35,427 Increase 10% 2005 $ 32,153 Increase 15% 2004 $ 27,989 Cost of goods sold increased by 10% in 2006 and by 15% in 2005 in comparison with the prior year. This compares against a 15% increase in revenues in 2006 and a 13% increase in revenues in 2005. Expressed as a percentage of revenues, cost of goods sold was 49%, 51% and 50% in 2006, 2005, and 2004 respectively. Overall margins in 2005 and 2004 were affected negatively by costs related to relocation of operating facilities in Chicago and Baltimore to Lansing and Lexington. Food Safety gross margins were 59%, 57% and 57% in 2006, 2005 and 2004, respectively. Changes in margins between periods relate primarily to changes in product mix. In fiscal 2004 and 2005, the Company increased overhead costs related to the new diagnostic manufacturing facility and the new ATP product introduction that adversely affected gross margins. Margins in 2005 were also adversely affected by the cost of moving the Company’s Acumedia unit and the start up costs of the new facility in Lansing. Food Safety margins sequentially increased during the 2005 fiscal year and more fully during the 2006 fiscal year as the effects of efficiencies resulting from investments in manufacturing facilities and the ATP change to manufacture this product internally began to be realized. Animal Safety gross margins were 43%, 42% and 42% in 2006, 2005 and 2004, respectively. Changes in margins between periods relate primarily to product mix. Margins in the 2004 year were adversely affected by costs related to the closing and move of the Company’s Ideal unit from Chicago to Lexington and Lansing.  neoGen coRPoRation manaGement’S DiScuSSion anD analySiS oF Financial conDition anD ReSultS oF oPeRationS oPeRatinG exPenSeS (dollars in thousands) Operating Expenses: Sales and Marketing General and Administrative Research and Development 2006 Increase (Decrease) 2005 Increase (Decrease) $ 15,799 6,174 2,988 17% 10% 9% $ 13,484 5,621 2,729 12% 12% (6%) 2004 $ 12,052 5,022 2,893 Sales and marketing expense categories increased in 2006 by 17% and increased by 12% in 2005 as compared with 2004. As a percentage of sales, sales and marketing expense increased in 2006 to 22% from 21% in 2005 and had decreased from 22% in 2004. These reduction of sales and marketing expense as a percentage of revenues in 2005 resulted from strong cost containment measures and certain more recent acquisitions that require relatively less sales and marketing support. Also, during 2004, a royalty agreement expired in which the Company was obligated to pay royalties to research corporation investors on natural toxin test kit sales. This royalty contributed 1% of the decrease in expenses. Management plans to continue to expand the Company’s sales and marketing efforts both domestically and internationally in the future and currently expects related expenses to remain between 20% and 25% expressed as a percentage of sales. General and administrative expenses increased by 10% in 2006 and by 12% in 2005. These expenses are generally fixed in relation to revenues; the increase in fiscal 2006 was due to overall increases in company wide activity. Increases in 2005 resulted primarily from the acquisition of Hacco in November 2003 as well as due to increased levels of operations of the Company. As a percentage of revenue, general and administrative expenses have decreased in all three years. These expenses do not vary as much with sales as compared to many other Company expenses. Research and development expenses increased by 9% in comparison with 2005 and decreased by 6% in 2005 in comparison with 2004. As a percentage of revenue these expenses were 4%, 4% and 5% in the years ended May 31, 2006, 2005 and 2004 respectively. Although some fluctuation in research and development expenses will occur, management expects research and development expenses to approximate 4% to 6% of revenues over time. These expenses approximate 8% to 10% of revenues from products and product lines that are supported by research and development. Certain Company products require relatively less in research and development expenses. oPeRatinG income (dollars in thousands) Operating Income 2006 $ 12,045 Increase 37% 2005 $ 8,769 Increase 16% 2004 $ 7,542 During fiscal year 2006 and 2005, the Company’s operating income increased by 37% and 16%. As a percentage of revenues it was 17%, 14% and 14% in 2006, 2005 and 2004 respectively. The Company has been successful in improving its operating income in 2006 from the positive effects of restructurings in 2005 and 2004, economies of sales and the effects of new acquisitions. otheR income (net) (dollars in thousands) Other Income—Interest and Other (Net) 2006 46 $ Increase (Decrease) (69%) 2005 147 $ Increase (Decrease) 11% 2004 132 $ Other income decreased by 69% in comparison with 2005 and increased by 11% in 2005 in comparison with 2004. Interest revenue and expense is a factor of the Company’s cash versus debt position in the periods. Debt exceeded interest earning assets over all three years. During 2005 and 2006 the Company recognized grant income of $250,000 in each year related to a grant from local governmental units. In 2004 royalty income was recognized from agreements that expired in that year. DeDicateD to FooD anD animal SaFety  manaGement’S DiScuSSion anD analySiS oF Financial conDition anD ReSultS oF oPeRationS FeDeRal anD State income taxeS (dollars in thousands) Federal and State Income Taxes 2006 $ 4,150 Increase 38% 2005 $ 3,000 Increase 17% 2004 $ 2,575 Federal and state income tax rates used in the computation of income tax expense in the periods remained comparable to those in the prior year. Expressed as a percentage of income before tax, such rates were 34% in each of the years. net income anD net income PeR ShaRe (dollars in thousands-except per share data) Net Income Net Income Per Share-Basic 2006 $ 7,941 .96 $ Increase 34% 2005 $ 5,916 .73 $ Increase 16% 2004 $ 5,099 .64 $ Net income and net income per share in 2004 was reduced by $300,000 or $.04 per share related to the closing of the Company’s Chicago area plant and the relocation of the operation to Lansing and Lexington and in 2005 was reduced by $220,000 or $ .03 per share related to the closing of the Company’s Acumedia production facility in Baltimore, Maryland and its transfer to a new facility in Lansing, Michigan. FutuRe oPeRatinG ReSultS Neogen Corporation’s future operating results involve a number of risks and uncertainties. Actual events or results may differ materially from those discussed in this report. Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed below as well as those discussed elsewhere in this report. Management’s ability to grow the business in the future depends upon its ability to successfully implement various strategies, including: • developing, manufacturing and marketing new products with new features and capabilities; • expanding the Company’s markets by fostering increased use of Company products by customers; • strengthening sales and marketing activities in geographies outside of the U.S.; • developing and implementing new technology development strategies; and • identifying and completing acquisitions that enhance existing businesses or create new business areas. Financial conDition anD liquiDity On May 31, 2006, the Company had $1,959,000 in cash and marketable securities, working capital of $26,252,000 and stockholders’ equity of $64,548,000. In addition to cash and security balances, a bank line with unused borrowings of $7,545,000 was available to, if necessary, support ongoing operations or to make acquisitions. Cash and marketable securities decreased $13,000 during 2006. Cash provided from operations was $12,313,000, additions to property and equipment and other non-current assets used cash of $2,692,000 and borrowings on the Company’s credit facility totaled $9,955,000 at May 31, 2006. Accounts receivable increased $2,647,000 or 25% when compared to May 31, 2005. This resulted from the business acquisitions during 2006 and from increased sales. Days sales outstanding remained at 56 days. Inventory levels increased 28% or $3,830,000 in 2006 as compared to 2005. This increase is primarily due to the acquisitions during the year. The Company maintains sufficient levels of inventory to assure that customer demands can be met on a timely basis. Acquisitions of long-lived assets totaled $2,309,000 and resulted from purchases and renovations of new manufacturing facilities and equipment for the Food Safety segment and other expenditures during the year. Net goodwill and non-amortizable intangible assets increased by $10,338,000 in 2006 primarily as the result of the acquisition of the dairy antibiotics testing business of UCB and from the purchase of Centrus International. These acquisitions have been accounted for on a preliminary basis. On June 2, 2006, the Company announced that it had completed an offering of 800,000 shares of which 650,000 were sold by the Company and 150,000 were sold by two members of management, for an aggregate purchase price of approximately $16.0 million. The net proceeds of the offering to the Company were approximately $12,237,000 after deducting the placement agency fees and offering expenses that were payable by the Company.  neoGen coRPoRation manaGement’S DiScuSSion anD analySiS oF Financial conDition anD ReSultS oF oPeRationS The Company did not receive any proceeds from the sale of the shares by the Selling Stockholders. Proceeds were used to repay the Company’s borrowings and add to working capital. contRactual oBliGationS The Company has the following contractual obligations due by period: (dollars in thousands) Long-Term Debt Operating Leases Unconditional Purchase Obligations Total $ 9,955 562 7,361 $ 17,878 Less than one year $ — 241 7,361 $ 7,602 1-3 years $ 9,955 306 — $ 10,261 More than 3-5 years $ — 15 — 15 $ 5 years $ — — — $ — Neogen has been profitable from operations for its last 53 quarters and has generated positive cash flow from operations during the period. However, the Company’s current funds may not be sufficient to meet the Company’s cash requirements to commercialize products currently under development or its plans to acquire additional technology and products that fit within the Company’s mission statement. Accordingly, the Company may be required to issue equity securities or enter into other financing arrangements for a portion of the Company’s future capital needs. The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, will not have a material effect on its results of operations or financial position. new accountinG PRonouncementS See discussion of any New Accounting Pronouncements in Note 1 to Consolidated Financial Statements. DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: conSoliDateD Balance SheetS May 31, Assets Current Assets Cash Marketable securities Accounts receivable, less allowance of $530,000 and $531,000 Inventories Deferred income taxes Prepaid expenses and other current assets Total Current Assets Property and Equipment Land and improvements Buildings and improvements Machinery and equipment Furniture and fixtures Less accumulated depreciation Net Property and Equipment Other Assets Goodwill Other non-amortizable intangible assets Other non-current assets, net of accumulated amortization of $1,527,000 and $1,123,000 Total Other Assets Liabilities and Stockholders’ Equity Current Liabilities Accounts payable Accruals Compensation and benefits Federal income taxes Other Total Current Liabilities Long-Term Debt Deferred Income Taxes Other Long-Term Liabilities Total Liabilities Stockholders’ Equity Preferred stock, $1.00 par value - shares authorized 100,000; none issued and outstanding Common stock, $0.16 par value - shares authorized 20,000,000; 8,310,624 and 8,147,011 shares issued and outstanding Additional paid-in capital Accumulated other comprehensive income Retained earnings Total Stockholders’ Equity 2006 2005 $ $ 1,809,000 150,000 13,116,000 17,626,000 1,264,000 2,304,000 36,269,000 970,000 9,403,000 11,159,000 606,000 22,138,000 (7,883,000) 14,255,000 1,972,000 — 10,469,000 13,796,000 768,000 1,374,000 28,379,000 902,000 8,809,000 8,590,000 528,000 18,829,000 (6,636,000) 12,193,000 28,937,000 2,076,000 6,753,000 37,766,000 $ 88,290,000 18,599,000 2,076,000 2,637,000 23,312,000 63,884,000 $ $ 2,832,000 $ 2,348,000 1,642,000 876,000 4,667,000 10,017,000 9,955,000 1,981,000 1,789,000 23,742,000 1,342,000 339,000 1,706,000 5,735,000 — 1,300,000 2,014,000 9,049,000 — — 1,330,000 28,600,000 85,000 34,533,000 64,548,000 $ 88,290,000 1,304,000 26,803,000 136,000 26,592,000 54,835,000 63,884,000 $ See accompanying notes to consolidated financial statements.  neoGen coRPoRation Year Ended May 31, Net Sales Cost of Goods Sold Gross Margin Operating Expenses Sales and marketing General and administrative Research and development Operating Income Other Income (Expense) Interest income Interest expense Grant income and other Income Before Income Taxes Income Taxes Net Income Net Income Per Share Basic Diluted neoGen coRPoRation anD SuBSiDiaRieS: conSoliDateD StatementS oF income 2006 $ 72,433,000 35,427,000 37,006,000 2005 $ 62,756,000 32,153,000 30,603,000 2004 $ 55,498,000 27,989,000 27,509,000 15,799,000 6,174,000 2,988,000 24,961,000 12,045,000 80,000 (283,000) 249,000 46,000 12,091,000 4,150,000 7,941,000 $ 13,484,000 5,621,000 2,729,000 21,834,000 8,769,000 7,000 (83,000) 223,000 147,000 8,916,000 3,000,000 5,916,000 $ 12,052,000 5,022,000 2,893,000 19,967,000 7,542,000 48,000 (61,000) 145,000 132,000 7,674,000 2,575,000 5,099,000 $ $ $ .96 .92 .64 .61 See accompanying notes to consolidated financial statements. .73 .70 $ $ $ $ DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: conSoliDateD StatementS oF StockholDeRS’ equity Common Stock Shares 7,750,607 Amount $ 1,240,000 Additional Paid-in Capital $ 24,582,000 Accumulated Other Comprehensive Income 3,000 $ Retained Earnings $ 15,577,000 Total Stockholders’ Equity $ 41,402,000 Balance, June 1, 2003 Exercise of options, including $250,000 income tax benefit 254,573 41,000 1,148,000 5,042 1,000 55,000 1,189,000 56,000 5,099,000 96,000 5,195,000 5,099,000 96,000 Issuance of shares under Employee Stock Purchase Plan Comprehensive income: Net income for 2004 Foreign currency translation adjustments Total comprehensive income Balance, May 31, 2004 Exercise of options and warrants, including $219,000 income tax benefit Issuance of warrants Issuance of shares under Employee Stock Purchase Plan Repurchase of common stock Comprehensive income: Net income for 2005 Foreign currency translation adjustments Total comprehensive income Balance, May 31, 2005 Exercise of options and warrants, including $703,000 income tax benefit Issuance of warrants Issuance of shares under Employee Stock Purchase Plan Repurchase of common stock Comprehensive income: Net income for 2006 Foreign currency translation adjustments Total comprehensive income Balance, May 31, 2006 8,010,222 1,282,000 25,785,000 99,000 20,676,000 47,842,000 149,816 24,000 1,117,000 55,000 6,895 (19,922) 1,000 (3,000) 100,000 (254,000) 1,141,000 55,000 101,000 (257,000) 8,147,011 1,304,000 26,803,000 136,000 26,592,000 54,835,000 5,916,000 37,000 5,916,000 37,000 5,953,000 154,786 25,000 1,626,000 51,000 10,865 (2,038) 2,000 (1,000) 148,000 (28,000) 1,651,000 51,000 150,000 (29,000) 7,941,000 7,941,000 8,310,624 $ 1,330,000 $ 28,600,000 $ 85,000 $ 34,533,000 (51,000) (51,000) 7,890,000 $ 64,548,000 See accompanying notes to consolidated financial statements.  neoGen coRPoRation neoGen coRPoRation anD SuBSiDiaRieS: conSoliDateD StatementS oF caSh FlowS Year Ended May 31, Cash Flows From Operating Activities Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization Deferred income taxes Income tax benefit of stock plan transactions Other Changes in operating assets and liabilities, net of business acquisitions: Accounts receivable Inventories Prepaid expenses and other current assets Accounts payable Accruals and other changes Net Cash From Operating Activities Cash Flows Used In Investing Activities Proceeds from sales of marketable securities Purchases of marketable securities Purchases of property, equipment and other noncurrent assets Business and product line acquisitions, net of cash acquired Net Cash Used In Investing Activities Cash Flows From (Used In) Financing Activities Net proceeds from issuance of common stock Repurchase of common stock Proceeds from long-term debt Payments on long-term debt Increase (Decrease) in other long-term liabilities Net Cash From (Used In) Financing Activities Net increase (decrease) in cash Cash, at beginning of year Cash, at end of year Supplemental Cash Flow Information Income taxes paid, net of refunds Interest paid 2006 2005 2004 $ 7,941,000 $ 5,916,000 $ 5,099,000 2,417,000 485,000 703,000 51,000 (1,346,000) (671,000) (930,000) 90,000 3,573,000 12,313,000 6,533,000 (6,683,000) (2,692,000) (20,658,000) (23,500,000) 1,098,000 (29,000) 14,640,000 (4,685,000) — 11,024,000 1,703,000 309,000 219,000 55,000 (545,000) (1,331,000) 256,000 (715,000) 855,000 6,722,000 831,000 (500,000) (2,688,000) (874,000) (3,231,000) 1,023,000 (257,000) — (3,900,000) 250,000 (2,884,000) 1,402,000 512,000 250,000 — (2,225,000) (831,000) (587,000) (210,000) (429,000) 2,981,000 39,019,000 (31,514,000) (5,043,000) (10,034,000) (7,572,000) 995,000 3,900,000 — — 4,895,000 (163,000) 1,972,000 $ 1,809,000 607,000 1,365,000 $ 1,972,000 304,000 1,061,000 $ 1,365,000 $ 1,863,000 283,000 $ 1,194,000 83,000 $ 2,249,000 53,000 See accompanying notes to consolidated financial statements. DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS . SummaRy oF accountinG PolicieS Nature of Operations Neogen Corporation develops, manufactures, and sells a diverse line of products dedicated to food safety testing and animal health applications. Basis of Consolidation The consolidated financial statements include the accounts of Neogen Corporation and its wholly owned subsidiaries (collectively, the Company). All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Comprehensive Income Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of stockholders’ equity. Accumulated other comprehensive income consists solely of foreign currency translation adjustments. Accounts Receivable and Concentrations of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit histories before extending credit and by monitoring credit exposure on a regular basis. An allowance for possible losses on accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. No single customer accounted for more than 10% of accounts receivable at May 31, 2006 and 2005. Fair Values of Financial Instruments The carrying amounts of marketable securities, accounts receivable, accounts payable, accrued expenses and long- term debt approximate fair value based on either their short maturity or current terms for similar instruments. Marketable Securities All marketable securities are classified as available-for-sale and are used to support current operations or to take advantage of short term investment opportunities. These securities are stated at estimated fair market value that approximates cost. The cost of securities sold is based on the specific identification method. Inventories Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories were as follows: Raw materials Work-in-process Finished goods $ 2006 8,033,000 411,000 9,182,000 $ 17,626,000 2005 $ 5,529,000 721,000 7,546,000 $ 13,796,000 Property and Equipment Property and equipment is stated at cost. Expenditures for major improvements are capitalized while repairs and maintenance are charged to expense. Depreciation is provided on the straight-line method over the estimated useful lives of the respective assets, which are generally seven to thirty-nine years for buildings and improvements and three to five years for furniture, machinery and equipment. Depreciation expense was $1,779,000, $1,444,000 and $1,180,000, in 2006, 2005 and 2004, respectively. Goodwill and Intangible Assets Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts allocated to other intangible assets. Other intangible assets include customer relationships, 0 neoGen coRPoRation neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS trademarks, trade names and patents. Amortizable intangible assets are amortized on either an accelerated or a straight-line basis over five to 20 years. The Company reviews the carrying amounts of goodwill and other non- amortizable intangible assets annually to determine if such assets may be impaired. If the carrying amounts of these assets are not recoverable based upon a discounted cash flow analysis, such assets are reduced by the estimated shortfall of fair value to recorded value. Long-lived Assets Management reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in business conditions indicate that the carrying amount of the assets may not be recoverable. Impairment is evaluated on the basis of undiscounted future cash flows from operations before interest for the remaining useful life of the assets. If present, impairment is measured based on the difference between fair value and the net book value of the related assets. Any long-lived assets held for disposal are reported at the lower of these net book values or fair value less estimated costs of disposal. Reclassification Certain amounts in the 2005 and 2004 financial statements have been reclassified to conform to the 2006 presentation. Stock Options The Company follows Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees, in accounting for its stock option plans. Under Opinion No. 25, no compensation expense is recognized because the exercise price of the Company’s stock options equals the market price of underlying stock on the date of grant. Had compensation expense for the Company’s stock-based compensation plans been determined based on the fair value at the grant dates for awards under those plans consistent with Statement of Financial Accounting Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, the Company’s net income and net income per share would have been as follows: Net income As reported Deduct-compensation expense based on fair value method Pro forma Basic net income per share As reported Pro forma Diluted net income per share As reported Pro forma 2006 2005 2004 $ 7,941,000 $ 5,916,000 $ 5,099,000 (793,000) $ 7,148,000 (824,000) $ 5,092,000 (702,000) $ 4,397,000 $ $ $ $ .96 .87 .92 .85 $ $ $ $ .73 .63 .70 .61 $ $ $ $ .64 .56 .61 .53 The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions for grants in 2006, 2005 and 2004, respectively: dividend yield of 0%; expected volatility of 44.5%, 44.5% and 47.0%; risk free interest rates of 4.90%, 3.25% and 2.7%; and expected lives of four years. The weighted average grant date fair value of options granted in 2006, 2005 and 2004 was $6.37, $6.06 and $6.03, respectively. Revenue Recognition Revenue from sales of products is recognized at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership, which is at the time of shipment. Where right of return exists, allowances are made at the time of sale to reflect expected returns based on historical experience. Shipping and Handling Costs Shipping and handling costs that are charged to and reimbursed by the customer are recognized as sales, while the related expenses incurred by the Company are recorded in sales and marketing expense and totaled $3,223,000, $2,649,000 and $2,164,000 in 2006, 2005, 2004, respectively. DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS Research and Development Research and development expenditures are charged to operations as incurred. Limited Partnership Royalty Income and Expense Royalty income from a related research limited partnership (included as a component of other income) was $132,000 in 2004. Royalty expense paid to a related research limited partnership (included as a component of sales and marketing expense) was $281,000 in 2004. The agreement governing royalty expense paid to a limited partnership expired in October 2003. At that time, substantially all royalty expense and limited partnership income ceased. Income Taxes The Company accounts for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense (credit) represents the change in net deferred income tax assets and liabilities during the year. No provision has been made for United States federal income taxes that may result from future remittances of the undistributed earnings of Neogen Europe, Ltd. because it is expected that such earnings will be reinvested overseas indefinitely. Advertising Costs Advertising costs are expensed as incurred and totaled $364,000, $264,000 and $258,000 in 2006, 2005, and 2004, respectively. Net Income Per Share Basic net income per share is based on the weighted average number of common shares outstanding during each year. Diluted earnings per share is based on the weighted average number of common shares and dilutive potential common shares outstanding. The Company’s dilutive potential common shares outstanding during the years result entirely from dilutive stock options and warrants. The following table presents the net income per share calculations: Year ended May 31, Numerator for basic and diluted net income per share 2006 2005 2004 Net income $ 7,941,000 $ 5,916,000 $ 5,099,000 Denominator Denominator for basic net income per share weighted average shares Effect of dilutive stock options and warrants Denominator for diluted net income per share Net income per share Basic Diluted 8,246,871 397,237 8,644,108 8,096,683 394,900 8,491,583 7,910,863 465,742 8,376,605 $ $ .96 .92 $ $ .73 .70 $ $ .64 .61 In 2006 and 2005, approximately 100,000 options were excluded from the computations of net income per share as the result of option prices exceeding the average market price of the common shares. No options were excluded in 2004. New Accounting Pronouncements In December 2004, the Financial Accounting Standards Board (FASB) issued a revision to Statement No. 123, Share-Based Payment. This revision supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and its related implementation guidance and requires companies to recognize the cost of stock options, based on the grant date fair value, granted pursuant to their employee stock option plans over the period during which the recipient is required to provide services in exchange for the options, typically the vested period. Pursuant to the requirements of the Statement, the Company plans to adopt the provisions of the Statement during the first quarter of 2007 using the retrospective method. The pro forma effect of adopting this Statement is disclosed above and is not expected to have a material impact in the trend of net income. In July 2006, the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes-an interpretation of FASB Statement No. 109 (FIN 48), which clarifies the accounting for uncertainty in tax positions.  neoGen coRPoRation neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS This Interpretation requires that the Company recognize in their financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. This interpretation is effective for fiscal years beginning after December 15, 2006, with the cumulative effect of the change in accounting principle recorded as an adjustment to opening retained earnings. The Company has not yet determined the effect of this interpretation on its financial statements. . GooDwill anD otheR intanGiBle aSSetS The Company follows the provisions of SFAS No. 142, Goodwill and Other Intangible Assets. SFAS No. 142 prohibits the amortization of goodwill and intangible assets with indefinite lives and requires that the Company evaluate these intangibles for impairment on an annual basis. Management has completed the required annual impairment tests of goodwill and intangible assets with indefinite lives as prescribed by SFAS No. 142 as of the first day of the fourth quarter of 2006 and determined that recorded amounts were not impaired and that no write-down was necessary. The following table summarizes goodwill by business segment: Balance, May 31, 2004 Goodwill acquired (adjusted) Balance, May 31, 2005 Goodwill acquired Balance, May 31, 2006 $ Food Safety 6,309,000 239,000 6,548,000 10,338,000 $ 16,886,000 Animal Safety $ 12,308,000 (257,000) 12,051,000 — $ 12,051,000 Non-amortizable intangible assets include licenses of $377,000, trademarks of $475,000, and customer relationship intangibles of $1,224,000. Other amortizable intangible assets consisted of the following and are included in other noncurrent assets within the consolidated balance sheets: Licenses Covenants not to compete Patents Customer relationship intangibles Balance, May 31, 2005 Licenses Covenants not to compete Patents Customer relationship intangibles Balance, May 31, 2006 Gross Carrying Amount 1,174,000 310,000 464,000 1,221,000 3,169,000 1,172,000 260,000 491,000 5,688,000 7,611,000 $ $ $ $ Less Accumulated Amortization 367,000 257,000 365,000 134,000 1,123,000 391,000 233,000 300,000 639,000 1,563,000 $ $ $ $ $ $ $ $ Net Carrying Amount 807,000 53,000 99,000 1,087,000 2,046,000 781,000 27,000 191,000 5,049,000 6,048,000 Amortization expense for other intangibles totaled $638,000, $259,000 and $222,000 in 2006, 2005 and 2004, respectively. The estimated amortization expense for each of the five succeeding years is as follows: $770,000 in 2007, $768,000 in 2008, $752,000 in 2009, $728,000 in 2010 and $727,000 in 2011. All goodwill and other intangible amounts related to fiscal 2006 are preliminary and are subject to adjustment upon finalization of purchase accounting for 2006 acquisitions. . maRketaBle SecuRitieS The Company invests in only high quality, short-term investments with maturity dates of less than one year that are classified as available-for-sale. As such, there were no significant differences between cost and estimated fair market value at May 31, 2006 and 2005. Additionally, since investments are short-term and carried to maturity, there were no realized gains and losses in 2006, 2005 or 2004. At May 31, 2006 marketable securities consisted solely of certificates of deposit. DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS . BuSineSS anD PRoDuct line acquiSitionS The Consolidated Statements of Income reflect the results of operations for business and product line acquisitions since the respective dates of purchase. As of February 28, 2003, the Company acquired the outstanding common stock of Adgen Ltd. of Ayr, Scotland. During fiscal 2006 the final payment of $180,000 was made under the purchase agreement. On November 21, 2003, Neogen Corporation purchased 100% of the common stock of Hacco, Inc. and of Hess & Clark, Inc. from United Agri Products, Inc., a then wholly owned subsidiary of ConAgra, Inc. Hacco has principal offices in Randolph, Wisconsin, and is a producer of rodenticide products. The Hess & Clark acquisition was principally a product line purchase in which the Company acquired lines of disinfectants and antibacterials. Consideration for the November 21, 2003 acquisitions was $10,000,000 in cash, including related acquisition costs. Allocation of the purchase price included current assets of $1,800,000; property, plant and equipment of $2,600,000; intangible assets of $7,400,000 (including customer intangibles of $1,900,000; patents and trademarks of $200,000 and goodwill of $5,300,000); and liabilities of $1,800,000, including an environmental remediation liability of $1,200,000. The portion of the customer based asset considered to have a definite life is expected to be amortized by accelerated methods over 20 years. The companies are believed to be strong synergistic fits into Neogen’s overall stability of providing food and animal safety solutions. Unaudited pro forma financial information, as if the acquisitions of Hacco and Hess & Clark had taken place on June 1, 2003 is as follows: Year ended May 31, Revenue Net income Diluted net income per share 2004 (In thousands except per share amount) $ 61,898 $ 5,696 .68 $ As of October 1, 2004, Neogen Europe, Ltd., the Company’s subsidiary in Scotland, UK, acquired the distribution business of BiologischeAnalysensysteme GmbH (BAG), a privately held company based in Lich, Germany. BAG was a distributor of Neogen Corporation’s products in Germany. BAG’s revenues in the 12 months ended September 30, 2004 were approximately $600,000. Consideration for the acquisition was cash of $448,000. The allocation of the purchase price included inventory of $68,000, equipment of $21,000 and customer based intangibles of $359,000. As of October 1, 2005 the Company made a second payment of $180,000 related to the revenues of BAG in the first year following the acquisition. The acquisition is expected to improve distribution of the Company’s products in Germany. On October 13, 2004, the Company acquired the UriCon product line of Animal Health Ventures, Inc., a privately held company. UriCon is a product used for the treatment of urinary incontinence in dogs. Consideration for the purchase was cash of $200,000. The allocation of the purchase price included inventory of $23,000 and intangibles of $177,000. The acquisition adds to the Company’s product lines directed toward the treatment of medical disorders in companion animals. On December 19, 2005, Neogen Corporation purchased certain assets of the dairy antibiotics business of UCB FD Bioproducts, a division of Belgium based UCB Group. Consideration for the sale, including transaction costs of $500,000, was $17,100,000 in cash, and post closing adjustments and potential secondary payments of up to $2,400,000. The preliminary allocation of the purchase price, subject to finalization of asset valuations, included $1,000,000 of accounts receivable, $2,900,000 of inventory, $1,200,000 of fixed assets, $7,600,000 of goodwill and $4,400,000 of other amortizable intangibles. Other amortizable intangibles have primarily been assigned 10 year lives. The dairy antibiotic business is believed to be a strong synergistic fit into Neogen’s overall strategy of providing food and animal safety solutions. Intangible assets in this transaction are expected to be deducted for tax purposes as amortized.  neoGen coRPoRation neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS Unaudited pro forma financial information, as if the acquisition of the dairy antibiotics business had taken place on June 1, 2003 is as follows: Years Ended May 31, Revenue Net Income Diluted net income per share 2006 $ $ 76,828 8,773 1.01 2005 2004 (In thousands except per share amounts) 63,768 6,817 .81 71,958 8,010 .95 $ $ $ $ On February 17, 2006, Neogen Corporation purchased the common stock of Centrus International, Inc., a wholly owned subsidiary of Eastman Chemical Company, of Kingsport, Tennessee. Consideration consisted of $3,300,000 in cash. The preliminary allocation of the purchase price included accounts receivable of $280,000, inventory of $270,000, fixed assets of $180,000, goodwill of $2,600,000 and deferred tax assets of $300,000 related to net operating loss carryforwards and assumed liabilities of $430,000. Centrus produces Soleris™, a user-friendly, rapid optical testing system that accurately detects microbial contamination and represents a synergistic fit with Neogen’s Food Safety solutions. Centrus unaudited sales in the 12 month period ended December 31, 2005 (prior to the acquisition) were $2,800,000. Intangible assets in this transaction are not expected to be deducted for tax purposes as amortized. . lonG-teRm DeBt On December 19, 2005, the Company executed a financing agreement with a bank ($9,955,000 drawn at May 31, 2006) providing for an unsecured revolving line of credit of $17,500,000 that matures on December 1, 2007. Amounts drawn at May 31, 2006 were repaid after year-end in conjunction with the stock offering discussed in Note 14. Interest is at LIBOR plus 95 basis points (rate under the terms of the agreement was 6.03% at May 31, 2006). Financial covenants include maintaining specified funded debt to EBITDA and debt service ratios as well as specified levels of tangible net worth, all of which are complied with at May 31, 2006. The agreement replaced an existing credit facility with another bank. . equity comPenSation PlanS Qualified and non-qualified options to purchase shares of common stock may be granted to directors, officers and employees of the Company at an exercise price of not less than the fair market value of the stock on the date of grant under the terms of the Company’s stock option plans. The number of shares initially authorized for issuance under the plans is 4,074,219. Remaining shares available for grant under stock option plans were 804,175, 985,731 and 151,606 at May 31, 2006, 2005 and 2004. Options vest over periods ranging from three to five years and option terms range from five to ten years. The following is a summary of stock option plan activity: Outstanding at June 1, 2003 (362,858 exercisable) Granted Exercised Forfeited Outstanding at May 31, 2004 (301,839 exercisable) Granted Exercised Forfeited Outstanding at May 31, 2005 (455,732 exercisable) Granted Exercised Forfeited Outstanding at May 31, 2006 (587,631 exercisable) Shares 1,163,343 353,125 (312,160) (1,562) 1,202,746 198,500 (149,502) (32,625) 1,219,119 202,250 (172,570) (20,694) 1,228,105 Weighted-Average Exercise Price 7.97 $ 15.21 6.05 8.13 10.53 19.36 6.77 13.74 12.31 18.41 7.15 16.73 $ 14.02 DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS The following is a summary of stock options outstanding at May 31, 2006: Options Outstanding Options Exercisable $ Range of Exercise Price 5.00 – 6.20 9.52 – 11.12 15.20 – 20.45 $ 5.00 – 20.45 Number 37,287 492,934 697,884 1,228,105 Average Remaining Contractual Life (Years) 3.7 3.0 5.3 4.3 Weighted- Average Exercise Price $ 5.18 10.16 17.21 $ 14.02 Weighted- Average Exercise Price $ 5.18 10.20 16.13 $ 11.82 Number 37,287 357,886 192,458 587,631 The weighted-average exercise price of shares that were exercisable at May 31, 2005 and 2004 was $9.98 and $8.26. The following table summarizes warrant activity with non-employees that are expensed at fair value. All warrants are exercisable for common stock of the Company and expire through 2011. Outstanding warrants at June 1, 2003 Warrants exercised during the year Warrants granted during the year Outstanding warrants at May 31, 2004 Warrants exercised during the year Warrants granted during the year Outstanding warrants at May 31, 2005 Warrants exercised during the year Warrants granted during the year Warrants forfeited during the year Outstanding warrants at May 31, 2006 Shares 36,875 (6,250) 15,000 45,625 (10,000) 13,000 48,625 (3,750) 11,000 (1,250) 54,625 Weighted-Average Exercise Price $ 9.21 10.48 15.20 11.01 9.43 18.19 13.15 5.50 17.61 5.50 $ 14.53 Common stock totaling 100,000 shares is reserved for issuance under the terms of the 2002 Employee Stock Purchase Plan. The plan gives eligible employees the option to purchase common stock (total purchases in any year are limited to 10% of compensation) at 95% of the lower of the market value of the stock at the beginning or end of each participation period. Shares purchased by employees were 10,865, 6,895 and 5,042 in 2006, 2005 and 2004, respectively. . income taxeS The provision for income taxes consisted of the following: Year ended May 31, Current: U.S. Federal and foreign State Deferred 2006 2005 2004 $ 3,310,000 355,000 485,000 $ 4,150,000 $ 2,395,000 296,000 309,000 $ 3,000,000 $ 1,729,000 334,000 512,000 $ 2,575,000  neoGen coRPoRation neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred income tax liabilities and assets are as follows: May 31, Deferred income tax liabilities Depreciation and amortization Intangible assets and other Deferred income tax assets Inventories and accounts receivable Acquired net operating loss carryforwards Net deferred income tax liabilities 2006 2005 $ (2,274,000) 293,000 (1,981,000) $ (1,590,000) 290,000 (1,300,000) 964,000 300,000 1,264,000 (717,000) $ 768,000 — 768,000 (532,000) $ Net operating loss carryforwards resulting in a deferred tax asset of $300,000 will expire in 2019. The reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax expense is as follows: Year ended May 31, Tax at U.S. statutory rates Tax credits and other Provisions for state income taxes, net of federal benefit 2006 $ 4,111,000 (195,000) 2005 $ 3,031,000 (226,000) 2004 $ 2,609,000 (254,000) 234,000 $ 4,150,000 195,000 $ 3,000,000 220,000 $ 2,575,000 . commitmentS anD continGencieS The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. Remaining anticipated cost of remediation through 2024 have been discounted at 4% and recorded within other long term liabilities in the consolidated balance sheet at its net present value of $1,016,000 at May 31, 2006. Estimated payments over the succeeding five years are $90,000 annually, with $1,170,000 due thereafter. The Company has agreements with related research limited partnerships and unrelated third parties that provide for the payment of royalties on the sale of certain products. Royalty expense, including amounts paid to related research limited partnerships, under the terms of these agreements for 2006, 2005 and 2004 was $911,000, $742,000 and $900,000 respectively. The Company leases office and manufacturing facilities under noncancelable operating leases. Rent expense for 2006, 2005 and 2004 was $239,000, $205,000 and $574,000, respectively. Future minimum rental payments for these leases over the remaining terms are as follows: 2007 - $241,000; 2008 - $205,000; 2009 - $101,000 and 2010 - $15,000. The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, will not have a material effect on its future results of operations or financial position. . DeFineD contRiBution BeneFit Plan The Company maintains a defined contribution 401(k) benefit plan covering substantially all employees. Employees are permitted to defer up to 15% of compensation, with the Company matching 100% of the first 3% deferred and 50% of the next 2% deferred. The Company’s expense under this plan was $348,000, $343,000 and $323,000 in 2006, 2005 and 2004, respectively. 0. SeGment inFoRmation The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a complete line of consumable products marketed to veterinarians and animal health product distributors. DeDicateD to FooD anD animal SaFety  neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS Additionally, the Animal Safety segment produces and markets a line of rodenticides to assist in the control of rats and mice in and around agricultural, food production and other facilities. These segments are managed separately because they represent strategic business units that offer different products and require different marketing strategies. The Company evaluates performance based on total sales and operating income of the respective segments. The accounting policies of the segments are the same as those described in Note 1. Segment information is as follows: 2006 Net sales to external customers Operating income Depreciation and amortization Interest income Interest expense Income taxes Total assets Expenditures for long-lived assets 2005 Net sales to external customers Operating income Depreciation and amortization Interest income Interest expense Income taxes Total assets Expenditures for long-lived assets 2004 Net sales to external customers Operating income Depreciation and amortization Interest income Interest expense Income taxes Total assets Expenditures for long-lived assets Food Safety Animal Safety Corporate and Eliminations (1) $ 34,951,000 6,753,000 1,593,000 — — 2,318,000 52,869,000 2,049,000 $ 28,156,000 4,051,000 908,000 — — 1,386,000 27,378,000 1,828,000 $ 27,567,000 4,223,000 782,000 — — 1,423,000 24,079,000 2,081,000 $ 37,482,000 6,083,000 824,000 — — 2,088,000 35,970,000 643,000 $ 34,600,000 5,284,000 795,000 — — 1,808,000 35,738,000 860,000 $ 27,931,000 3,679,000 620,000 — — 1,105,000 34,914,000 2,962,000 $ $ $ — (791,000) — 80,000 283,000 (256,000) (549,000) — — (566,000) — 7,000 83,000 (194,000) 768,000 — — (360,000) — 48,000 61,000 47,000 982,000 — Total $ 72,433,000 12,045,000 2,417,000 80,000 283,000 4,150,000 88,290,000 2,692,000 $ 62,756,000 8,769,000 1,703,000 7,000 83,000 3,000,000 63,884,000 2,688,000 $ 55,498,000 7,542,000 1,402,000 48,000 61,000 2,575,000 59,975,000 5,043,000 (1) Includes corporate assets, consisting of marketable securities, and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions and minority interests. Sales to customers outside the United States amounted to $20,750,000 or 29% of consolidated sales in 2006, $17,002,000 or 27% in 2005 and $13,781,000 or 25% in 2004 and were derived primarily in the geographic areas of South and Central America, Canada, Asia and Europe. The Company does not have sales to any single foreign country or customer exceeding 10% of consolidated net sales. . GoveRnment GRant The Company received a $500,000 grant from Ingham County in fiscal 2005 that was restricted for the purchase of machinery and equipment at its location in Lansing, Michigan. The grant was repayable in cash plus interest to the extent not offset by allowances for new employees hired in Lansing over a period of 6 years. Grant monies received from the County for eligible purchases were initially recognized as a long-term liability. The liability is reduced and other income was recognized for the allowances granted as eligible new employees were hired. The Company recognized other income of $250,000 in 2006 and 2005 related to the grant.  neoGen coRPoRation neoGen coRPoRation anD SuBSiDiaRieS: noteS to conSoliDateD Financial StatementS . Stock RePuRchaSe The Company’s Board of Directors has authorized the purchase of up to 1,250,000 shares of the Company’s common stock. As of May 31, 2006, 892,885 cumulative shares had been purchased in negotiated and open market transactions for a total price, including commissions, of approximately $5,226,000. There were no purchases in 2004. Shares purchased under this buy-back program were retired. . SummaRy oF quaRteRly Data (unauDiteD) $ $ August 2004 15,212 7,505 1,584 .20 .19 August 2005 16,778 8,841 2,140 .26 .25 Quarter Ended November 2004 February 2005 (In thousands, except per share data) $ 17,133 8,094 1,672 .21 .20 $ 14,403 6,958 1,214 .15 .14 Quarter Ended November 2005 February 2006 (In thousands, except per share data) $ 18,256 9,490 2,213 .27 .26 $ 17,584 8,522 1,632 .20 .19 $ $ May 2005 16,008 8,046 1,446 .18 .17 May 2006 19,815 10,153 1,956 .23 .22 Net sales Gross margin Net income Basic net income per share Diluted net income per share Net sales Gross margin Net income Basic net income per share Diluted net income per share Quarterly net income per share is based on weighted-average shares outstanding and potentially dilutive stock options and warrants for the specific period, and as a result, will not necessarily aggregate to total net income per share as computed for the year as disclosed in the consolidated statements of income. . SuBSequent event On June 7, 2006 the Company completed the sale of 650,000 shares of common stock. Gross proceeds to the Company were $13,000,000 before selling agent commissions and expenses of $763,000. Proceeds of the sale were used to retire long-term debt with the remainder available to fund future operating needs. DeDicateD to FooD anD animal SaFety  manaGement RePoRt on inteRnal contRol oveR Financial RePoRtinG & RePoRt oF inDePenDent ReGiSteReD PuBlic accountinG FiRm manaGement RePoRt on inteRnal contRol oveR Financial RePoRtinG The Board of Directors and Stockholders of Neogen Corporation: The management of Neogen Corporation is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f). Neogen Corporation’s internal control system was designed to provide reasonable assurance to the Company’s management and Board of Directors regarding the preparation and fair presentation of published financial statements. Neogen Corporation’s management assessed the effectiveness of the Company’s internal control over financial reporting as of May 31, 2006 under the supervision and with the participation of the Chairman and CEO, and the Vice President and CFO. In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework. Based on that assessment, management believes that, as of May 31, 2006, the Company’s internal control over financial reporting is effective. Neogen Corporation’s independent registered public accounting firm, Ernst & Young LLP, has issued an attestation report on management’s assessment of the Company’s internal control over financial reporting (below). James L. Herbert Chairman & CEO August 8, 2006 Richard R. Current Vice President & CFO RePoRt oF inDePenDent ReGiSteReD PuBlic accountinG FiRm on Financial StatementS The Board of Directors and Stockholders of Neogen Corporation, We have audited the accompanying consolidated balance sheets of Neogen Corporation (the Company) and subsidiaries as of May 31, 2006 and 2005, and the related consolidated statements of income, stockholders’ equity, and cash flows for each of the three years in the period ended May 31, 2006. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Neogen Corporation and subsidiaries at May 31, 2006 and 2005, and the consolidated results of their operations and their cash flows for each of the three years in the period ended May 31, 2006, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of Neogen Corporation’s internal control over financial reporting as of May 31, 2006, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated August 8, 2006 expressed an unqualified opinion thereon. Grand Rapids, Michigan August 8, 2006 0 neoGen coRPoRation RePoRt oF inDePenDent ReGiSteReD PuBlic accountinG FiRm on inteRnal contRol oveR Financial RePoRtinG The Board of Directors and Stockholders of Neogen Corporation, We have audited management’s assessment, included in the accompanying Management’s Report on Internal Control over Financial Reporting, that Neogen Corporation and subsidiaries (the Company) maintained effective internal control over financial reporting as of May 31, 2006, based on criteria established in Internal Control— Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the Company’s internal control over financial reporting based on our audit. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit reparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. In our opinion, management’s assessment that Neogen Corporation and subsidiaries maintained effective internal control over financial reporting as of May 31, 2006, is fairly stated, in all material respects, based on the COSO criteria. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of May 31, 2006, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the fiscal 2006 consolidated financial statements of Neogen Corporation and subsidiaries and our report dated August 8, 2006 expressed an unqualified opinion thereon. Grand Rapids, Michigan August 8, 2006 DeDicateD to FooD anD animal SaFety  neoGen coRPoRation oFFiceRS anD DiRectoRS oFFiceRS James L. Herbert Chairman of the Board Chief Executive Officer Lon M. Bohannon President Chief Operating Officer Richard R. Current Vice President Chief Financial Officer Edward L. Bradley Vice President, Food Safety Kenneth V. Kodilla Vice President Manufacturing Joseph M. Madden, Ph.D. Vice President Scientific Affairs Anthony E. Maltese Vice President Corporate Development Terri A. Morrical Vice President, Animal Safety Mark A. Mozola, Ph.D. Vice President Research and Development Paul S. Satoh, Ph.D. Vice President Basic and Exploratory Research DiRectoRS James L. Herbert Chairman of the Board Chief Executive Officer Neogen Corporation Thomas H. Reed Secretary of the Board Special Assistant to the President Packerland Packing Company Jack C. Parnell Kahn, Soares & Conway Former Deputy Secretary U.S. Dept. of Agriculture Lon M. Bohannon President Chief Operating Officer Neogen Corporation Robert M. Book President, Agrivista, Inc. Former Vice President Elanco Products Company Gordon E. Guyer, Ph.D. Former President Michigan State University Leonard E. Heller, Ph.D. Professor, University of Kentucky CEO, Health Management Services, LLC G. Bruce Papesh President Dart, Papesh & Co. leGal council Lowe Law Firm, P.C. 2375 Woodlake Drive Suite 380 Okemos, MI 48864 Fraser Trebilcock Davis & Dunlap, P.C. 1000 Michigan National Tower Lansing, MI 48933 inDePenDent ReGiSteReD PuBlic accountinG FiRm Ernst & Young, LLP Suite 1000 171 Monroe Avenue NW Grand Rapids, MI 49503 FoRm 0-k anD the comPany’S coDe oF ethicS Copies of Form 10-K and the Company’s Code of Ethics will be provided upon request without charge to persons directing their request to: Neogen Corporation Attention: Investor Relations 620 Lesher Place Lansing, MI 48912 Stock tRanSFeR aGent anD ReGiStRaR American Stock Transfer & Trust Co. 40 Wall Street New York, NY 10005 annual meetinG 10:00 a.m. October 12, 2006 University Club of Michigan State University 3435 Forest Road Lansing, MI 48909 Stock PRoFile activity The Company’s common stock is traded in the over-the-counter market and quoted in the NASDAQ National Market System under the symbol NEOG. Price ranges reported are based on inter-dealer sale quotations, as reported by NASDAQ, without adjustments for markups, markdowns, or commissions typically paid by retail investors, and may not represent actual transactions. No cash dividends have ever been paid, and the Company does not currently anticipate paying cash dividends in the foreseeable future. As of July 31, 2006, there were approximately 5,000 holders of the Company’s common stock. Year Ended May 31, 2006 May 31, 2005 Fiscal Quarter First Quarter Second Quarter Third Quarter Fourth Quarter First Quarter Second Quarter Third Quarter Fourth Quarter High $ 17.40 $ 20.48 $ 23.15 $ 25.22 $ 20.00 $ 21.76 $ 23.00 $ 18.99 Low $ 13.50 $ 15.35 $ 19.75 $ 18.00 $ 15.86 $ 17.35 $ 17.00 $ 12.46  neoGen coRPoRation 

Continue reading text version or see original annual report in PDF format above